Pulse Biosciences (NASDAQ:PLSE) Upgraded to “Sell” at StockNews.com

StockNews.com upgraded shares of Pulse Biosciences (NASDAQ:PLSE) to a sell rating in a report issued on Friday.

Pulse Biosciences Stock Performance

Shares of PLSE stock opened at $17.87 on Friday. The firm has a market cap of $1.10 billion, a price-to-earnings ratio of -22.06 and a beta of 1.75. Pulse Biosciences has a 1 year low of $3.78 and a 1 year high of $22.69. The stock’s 50-day moving average is $17.63 and its two-hundred day moving average is $12.60.

Hedge Funds Weigh In On Pulse Biosciences

A number of hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets boosted its stake in Pulse Biosciences by 63.6% during the 1st quarter. BNP Paribas Financial Markets now owns 7,597 shares of the company’s stock worth $66,000 after purchasing an additional 2,952 shares during the period. Price T Rowe Associates Inc. MD acquired a new stake in shares of Pulse Biosciences during the first quarter worth about $88,000. Quest Partners LLC purchased a new position in shares of Pulse Biosciences during the second quarter worth about $91,000. Cetera Advisors LLC purchased a new position in shares of Pulse Biosciences during the first quarter worth about $109,000. Finally, PNC Financial Services Group Inc. acquired a new position in Pulse Biosciences in the 4th quarter valued at about $242,000. 76.95% of the stock is currently owned by hedge funds and other institutional investors.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.